Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2006 2
2007 1
2009 2
2010 1
2011 1
2013 1
2021 2
2022 13
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study).
Siripongboonsitti T, Ungtrakul T, Tawinprai K, Nimmol T, Buttakosa M, Sornsamdang G, Jarrusrojwuttikul T, Silapant P, Mahanonda N. Siripongboonsitti T, et al. Among authors: mahanonda n. Int J Infect Dis. 2023 Sep;134:211-219. doi: 10.1016/j.ijid.2023.06.018. Epub 2023 Jun 30. Int J Infect Dis. 2023. PMID: 37393041 Free article. Clinical Trial.
Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial).
Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C. Siripongboonsitti T, et al. Among authors: mahanonda n. Phytomedicine. 2023 Oct;119:155018. doi: 10.1016/j.phymed.2023.155018. Epub 2023 Aug 12. Phytomedicine. 2023. PMID: 37625206 Free article. Clinical Trial.
Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10-17 Years in Thailand.
Thonginnetra S, Tawinprai K, Niemsorn K, Promsena P, Tandhansakul M, Kasemlawan N, Ruangkijpaisal N, Banomyong N, Phattraprayoon N, Rangkakulnuwat P, Vanichsetakul P, Ungtrakul T, Wittayasak K, Thonwirak N, Soonklang K, Mahanonda N. Thonginnetra S, et al. Among authors: mahanonda n. Vaccines (Basel). 2022 Oct 21;10(10):1765. doi: 10.3390/vaccines10101765. Vaccines (Basel). 2022. PMID: 36298630 Free PMC article.
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.
Cohen G, Jungsomsri P, Sangwongwanich J, Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Cohen G, et al. Among authors: mahanonda n. Hum Vaccin Immunother. 2022 Nov 30;18(5):2052525. doi: 10.1080/21645515.2022.2052525. Epub 2022 Mar 24. Hum Vaccin Immunother. 2022. PMID: 35323079 Free PMC article.
Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients.
Maes M, Ruckoanich P, Chang YS, Mahanonda N, Berk M. Maes M, et al. Among authors: mahanonda n. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):769-83. doi: 10.1016/j.pnpbp.2010.06.008. Epub 2010 Jun 16. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 20561554 Review.
Pharmacokinetic Comparison of Favipiravir Oral Solution and Tablet Formulations in Healthy Thai Volunteers.
Siripongboonsitti T, Ungtrakul T, Watanapokasin N, Timsri P, Wongpakdee K, Wattanasin P, Pavitrapok C, Khunvichai A, Jamnongtanachot P, Mueannoom W, Kitpoka T, Arjharn W, Mahanonda N. Siripongboonsitti T, et al. Among authors: mahanonda n. Clin Pharmacol Drug Dev. 2023 Jan;12(1):14-20. doi: 10.1002/cpdd.1149. Epub 2022 Jul 25. Clin Pharmacol Drug Dev. 2023. PMID: 35877195 Clinical Trial.
Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Tawinprai K, et al. Among authors: mahanonda n. Expert Rev Vaccines. 2022 Dec;21(12):1873-1881. doi: 10.1080/14760584.2022.2099380. Epub 2022 Jul 13. Expert Rev Vaccines. 2022. PMID: 35792752 Clinical Trial.
34 results